Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure
Conditions
- Ischemic Heart Failure
- Chronic Heart Failure
Interventions
- BIOLOGICAL: Human (allogeneic) iPS-cell-derived cardiomyocyte
Sponsor
HELP Therapeutics Co., Ltd.
Collaborators